Kidney Cancer (Renal Cell Cancer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Kidney Cancer Pipeline Products Market Report Overview
Kidney cancer or renal cancer is a disease in which kidney cells become malignant (cancerous) and grow out of control, forming a tumor. Symptoms include blood in urine, loss of appetite, fever that lasts for weeks, extreme fatigue, anemia, shortness of breath, and bone pain. Treatment includes surgery, radiation therapy, and chemotherapy.
The kidney cancer pipeline market research report provides comprehensive information on the therapeutics under development for kidney cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for kidney cancer and features dormant and discontinued projects.
Kidney Cancer Pipeline Products Market Segmentation by Targets
The key targets in the kidney cancer pipeline products market are Programmed Cell Death 1 Ligand 1, Programmed Cell Death Protein 1, Cells Expressing Epidermal Growth Factor Receptor, Hepatocyte Growth Factor Receptor, Mast/Stem Cell Growth Factor Receptor Kit, and Vascular Endothelial Growth Factor Receptor 2 among others. Programmed Cell Death 1 Ligand 1 is the leading target in the pipeline.
Kidney Cancer Pipeline Products Market Analysis by Targets
For more target insights into the kidney cancer pipeline products market, download a free report sample
Kidney Cancer Pipeline Products Market Segmentation by Mechanisms of Action
The key mechanisms of action in the kidney cancer pipeline products market are Programmed Cell Death 1 Ligand 1 Inhibitor, Cytotoxic To Cells Expressing Epidermal Growth Factor Receptor, Programmed Cell Death Protein 1 Antagonist, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Interleukin 10 Receptor Agonist, Tumor Necrosis Factor Receptor Superfamily Member 9 Agonist, Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, and Hepatocyte Growth Factor Receptor Inhibitor among others. Programmed Cell Death 1 Ligand 1 Inhibitor is the leading MoA in the pipeline market.
Kidney Cancer Pipeline Products Market Analysis by Mechanisms of Action
For more mechanisms of action insights into the kidney cancer pipeline products market, download a free report sample
Kidney Cancer Pipeline Products Market Segmentation by Routes of Administration
The key routes of administration in the kidney cancer pipeline products market are intravenous, oral, subcutaneous, parenteral, topical, vaginal, and intratumor among others. Intravenous is the leading RoA.
Kidney Cancer Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights into the kidney cancer pipeline products market, download a free report sample
Kidney Cancer Pipeline Products Market Segmentation by Molecule Types
The key molecule types in the kidney cancer pipeline products market are small molecule, monoclonal antibody, cell therapy, synthetic peptide, fusion protein, gene-modified cell therapy, recombinant protein, monoclonal antibody conjugated, oncolytic virus, antisense oligonucleotide, and recombinant vector vaccine among others. The small molecule is the leading molecule type.
Kidney Cancer Pipeline Products Market Analysis by Molecule Types
For more molecule type insights into the kidney cancer pipeline products market, download a free report sample
Kidney cancer Pipeline Products Market - Competitive Landscape
Some of the leading companies in the kidney cancer pipeline products market are Deka Biosciences Inc, Bayer AG, Gilead Sciences Inc, Merck KGaA, Agenus Inc, Alligator Bioscience AB, Alphamab Oncology, Boehringer Ingelheim International GmbH, and Bristol-Myers Squibb Co among others. Deka Biosciences Inc is the leading company in the kidney cancer pipeline products market.
Kidney cancer Pipeline Products Market Analysis by Companies
To know more about the leading players in the kidney cancer pipeline products market, download a free report sample
Kidney cancer Pipeline Products Market Report Overview
Key Targets | Programmed Cell Death 1 Ligand 1, Programmed Cell Death Protein 1, Cells Expressing Epidermal Growth Factor Receptor, Hepatocyte Growth Factor Receptor, Mast/Stem Cell Growth Factor Receptor Kit, and Vascular Endothelial Growth Factor Receptor 2 |
Key Mechanisms of Action | Programmed Cell Death 1 Ligand 1 Inhibitor, Cytotoxic To Cells Expressing Epidermal Growth Factor Receptor, Programmed Cell Death Protein 1 Antagonist, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Interleukin 10 Receptor Agonist, Tumor Necrosis Factor Receptor Superfamily Member 9 Agonist, Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, and Hepatocyte Growth Factor Receptor Inhibitor |
Key Routes of Administration | Intravenous, Oral, Subcutaneous, Parenteral, Topical, Vaginal, and Intratumor |
Key Molecule Type | Small Molecules, Monoclonal Antibody, Cell Therapy, Synthetic Peptide, Fusion Protein, Gene-Modified Cell Therapy, Recombinant Protein, Monoclonal Antibody Conjugated, Oncolytic Virus, Antisense Oligonucleotide, and Recombinant Vector Vaccine |
Leading Companies | Deka Biosciences Inc, Bayer AG, Gilead Sciences Inc, Merck KGaA, Agenus Inc, Alligator Bioscience AB, Alphamab Oncology, Boehringer Ingelheim International GmbH, and Bristol-Myers Squibb Co |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of kidney cancer.
- The pipeline guide reviews pipeline therapeutics for kidney cancer by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in kidney cancer therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates kidney cancer therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for kidney cancer
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for kidney cancer.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding the kidney cancer pipeline depth and focus on Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
4SC AG
A28 Therapeutics Inc
AbbVie Inc
Actuate Therapeutics Inc
Adicet Bio Inc
Affimed GmbH
Agenus Inc
Alligator Bioscience AB
Almac Discovery Ltd
Alpha-1 Biologics Corp
Alphamab Oncology
Alpine Immune Sciences Inc
Anaveon AG
AntiCancer Inc
Apcure SAS
Apollomics Inc
Aravive Inc
Astellas Pharma Inc
AvenCell Europe GmbH
Avesthagen Ltd
Bavarian Nordic AS
Bayer AG
Beijing Foreland Pharma Co Ltd
Beijing Scitech-MQ Pharmaceuticals Ltd
BeyondSpring Inc
Bio-Thera Solutions Ltd
BioAtla Inc
BioNTech SE
Biosion Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Calviri Inc
CanBas Co Ltd
Canget BioTekpharma LLC
Celldex Therapeutics Inc
Centurion BioPharma Corp
Chongqing Precision Biotech Co Ltd
Clonz Biotech Pvt Ltd
COARE Biotechnology Inc
Coherent Biopharma
Corvus Pharmaceuticals Inc
Cothera Bioscience Pty Ltd
CSPC Pharmaceutical Group Ltd
CureLab Oncology Inc
CytomX Therapeutics Inc
Deciphera Pharmaceuticals Inc
Deka Biosciences Inc
DNAtrix Inc
Duet Therapeutics Inc
Dyadic International Inc
Elevation Oncology Inc
Enara Bio Ltd
Exelixis Inc
Fannin Innovation Studio
Faron Pharmaceuticals Oy
Gilead Sciences Inc
Glycotope GmbH
GSK plc
Guangzhou BeBetter Medicine Technology Co Ltd
Handa Pharmaceuticals LLC
Helixmith Co Ltd
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
ImmunityBio Inc
Imugene Ltd
Incyte Corp
Inmune Bio Inc
Innovative Cellular Therapeutics Co Ltd
IO Biotech Inc
iOmx Therapeutics AG
Jiangxi Jemincare Group Co Ltd
Johnson & Johnson
Jubilant Therapeutics Inc
Kind Pharmaceuticals
Komipharm International Co Ltd
Lantern Pharma Inc
Luye Pharma Group Ltd
MacroGenics Inc
Marino Biotechnology Co Ltd
MaxiVAX SA
MdBioLab
MedAnnex Ltd
Merck & Co Inc
Merck KGaA
Metagone Biotech Inc
Metis Precision Medicine
MicuRx Pharmaceuticals Inc
Midissia Therapeutics Inc
Millennium Pharmaceuticals Inc
Mina Therapeutics Ltd
Mirati Therapeutics Inc
Moleculin Biotech Inc
Multitude therapeutics Inc
Nanjing Aimeifei Biomedical Technology Co Ltd
NanoVation Therapeutics Inc
NeuClone Pty Ltd
Novartis AG
Oncolys BioPharma Inc
Oncovir Inc
OneThree Biotech Inc
Orion Corp
Orpheus Therapeutics Inc
Panorama Researchama Research
Pfizer Inc
PharmaTher Holdings Ltd
Pharmicell Co Ltd
Pharminogen Inc
Portage Biotech Inc
Poseida Therapeutics Inc
Propanc Biopharma Inc
Pyxis Oncology Inc
Qilu Pharmaceutical Co Ltd
Qu Biologics Inc
Quadriga BioSciences Inc
RemeGen Co Ltd
Repertoire Immune Medicines Inc
Rizen (Suzhou) Biosciences Co Ltd
SA Science Inc
Sanofi
Sareum Holdings Plc
Scancell Holdings Plc
Shanghai Escugen Biotechnology Co Ltd
Shanghai Pharmaceutical Group Co Ltd
Shanghai Pharmaceuticals Holding Co Ltd
Shattuck Labs Inc
Shenzhen Chipscreen Biosciences Co Ltd
Shijiazhuang Yiling Pharmaceutical Co Ltd
Sonnet BioTherapeutics Holdings Inc
ST Pharm Co Ltd
Statera Biopharma Inc
Suzhou Stainwei Biotech Inc
Suzhou Zerun New Drug Research and Development Co Ltd
TAE Life Sciences LLC
TotalClarity Inc
UbiVac Inc
Unicyte AG
Vault Pharma Inc
Versameb AG
Wntrix Inc
Xbrane Biopharma AB
Yuhan Corp
ZielBio Inc
Zylem Biosciences Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the kidney cancer pipeline products market?
The key targets in the kidney cancer pipeline products market are Programmed Cell Death 1 Ligand 1, Programmed Cell Death Protein 1, Cells Expressing Epidermal Growth Factor Receptor, Hepatocyte Growth Factor Receptor, Mast/Stem Cell Growth Factor Receptor Kit, and Vascular Endothelial Growth Factor Receptor 2.
-
What are the key mechanisms of action in the kidney cancer pipeline products market?
The key mechanisms of action in the kidney cancer pipeline products market are Programmed Cell Death 1 Ligand 1 Inhibitor, Cytotoxic To Cells Expressing Epidermal Growth Factor Receptor, Programmed Cell Death Protein 1 Antagonist, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Interleukin 10 Receptor Agonist, Tumor Necrosis Factor Receptor Superfamily Member 9 Agonist, Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, and Hepatocyte Growth Factor Receptor Inhibitor.
-
What are the key routes of administration in the kidney cancer pipeline products market?
The key routes of administration in the kidney cancer pipeline products market are intravenous, oral, subcutaneous, parenteral, topical, vaginal, and intratumor.
-
What are the key molecule types in the kidney cancer pipeline products market?
The key molecule types in the kidney cancer pipeline products market are small molecules, monoclonal antibody, cell therapy, synthetic peptide, fusion protein, gene-modified cell therapy, recombinant protein, monoclonal antibody conjugated, oncolytic virus, antisense oligonucleotide, and recombinant vector vaccine.
-
Which are the leading companies in the kidney cancer pipeline products market?
Some of the leading companies in the kidney cancer pipeline products market are Deka Biosciences Inc, Bayer AG, Gilead Sciences Inc, Merck KGaA, Agenus Inc, Alligator Bioscience AB, Alphamab Oncology, Boehringer Ingelheim International GmbH, and Bristol-Myers Squibb Co.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.